So now what?
That question comes to the fore now that the Oncologic Drugs Advisory Committee has completed its review of the status...
US FDA’s Accelerated Approval process has always been a deceptively simple idea. After a three-day public review of ‘dangling’ applications, the underlying complexity remains.
So now what?
That question comes to the fore now that the Oncologic Drugs Advisory Committee has completed its review of the status...